1. impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; 2. use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; 3. pregnancy; 4. history of serious adverse reactions such as transfusion anaphylaxis; 5. participation in another interventional clinical trial; 6. disagreement of attending physician; 7. disagreement of the patient or legal representative to participate in the study.

1. impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; 2. use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; 3. pregnancy; 4. history of serious adverse reactions such as transfusion anaphylaxis; 5. participation in another interventional clinical trial; 6. disagreement of attending physician; 7. disagreement of the patient or legal representative to participate in the study.

impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; pregnancy; history of serious adverse reactions such as transfusion anaphylaxis; participation in another interventional clinical trial; disagreement of attending physician; disagreement of the patient or legal representative to participate in the study.

impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; pregnancy; history of serious adverse reactions such as transfusion anaphylaxis; participation in another interventional clinical trial; disagreement of attending physician; disagreement of the patient or legal representative to participate in the study.

1. impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; 2. use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; 3. pregnancy; 4. history of serious adverse reactions such as transfusion anaphylaxis; 5. participation in another interventional clinical trial; 6. disagreement of attending physician; 7. disagreement of the patient or legal representative to participate in the study.

1. impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; 2. use of immunosuppressants for other underlying diseases, except corticosteroids for the sars-cov-2, in the last 30 days before enrollment; 3. pregnancy; 4. history of serious adverse reactions such as transfusion anaphylaxis; 5. participation in another interventional clinical trial; 6. disagreement of attending physician; 7. disagreement of the patient or legal representative to participate in the study.